However, a study of AURKA inhibitors in prostate cancer suggests that monotherapy with AURKA inhibitors is not effective in improving patient prognosis which may be partly due to compensatory survival pathways (Beltran et al., 2019). The gene discussed is AURKA; the disease is Familial prostate cancer.